Investigating how proline metabolism affects blood vessel function in pulmonary arterial hypertension.
Official title: Endothelial Proline Utilization in Pulmonary Arterial Hypertension
Funded at Brigham and Women's Hospital · NIH-10864353 · Data updated 2026-11-12
This study is looking at how a substance called proline affects blood vessel changes in people with pulmonary arterial hypertension (PAH), and it hopes to find new ways to help treat this condition.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $131,485 |
| NIH project number | 1R03HL172985-01 |
| Project ID | NIH-10864353 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage pulmonary arterial hypertension.
✕Less likely to help
Patients with advanced pulmonary arterial hypertension or those not diagnosed with the condition may not benefit from this research.
What this research studies
This research focuses on understanding the role of proline metabolism in pulmonary arterial hypertension (PAH), a condition that leads to severe complications like right ventricular failure. By using advanced imaging techniques and systems biology, the study aims to identify how proline dysregulation contributes to the remodeling of blood vessels in PAH. The research will involve both laboratory studies on endothelial cells and analysis of human samples to uncover metabolic changes associated with early-stage PAH. Patients may benefit from insights that could lead to new therapeutic strategies targeting metabolic pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for patients with pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in understanding metabolic pathways in other cardiovascular conditions, suggesting potential for success in this novel approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Wertheim, Bradley — Brigham and Women's Hospital
- Study coordinator: Wertheim, Bradley
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.